DuoNeb® is indicated for the treatment of bronchospasm associated with COPD for patients requiring more than one bronchodilator. In a 12-week clinical study, the most common adverse reactions reported with DuoNeb® Inhalation Solution were chest pain, pharyngitis, diarrhea, bronchitis, nausea, and leg cramps. Albuterol sulfate can have a significant cardiovascular effect, significant hypokalemia, and the potential life-threatening paradoxical bronchospasm. Caution is advised in patients with convulsive disorders, hyperthyroidism, diabetes mellitus, narrow-angle glaucoma, prostatic hypertrophy, or bladder-neck obstruction. Co-administration of DuoNeb® Inhalation Solution and other sympathomimetic agents may increase the risk of adverse cardiovascular effects.
© 2007 Dey, L.P. SAFETY INFORMATION   .   PATIENT PRESCRIBING INFORMATION   .   FULL PRESCRIBING INFORMATION PRIVACY POLICY   .   CONTACT US   .   REFERENCES   .   SITE MAP Please read this important safety information about DuoNeb® DuoNeb® is indicated for the treatment of bronchospasm associated with COPD for patients requiring more than one bronchodilator. In a 12-week clinical study, the most common adverse reactions reported with DuoNeb® Inhalation Solution were chest pain, pharyngitis, diarrhea, bronchitis, nausea, and leg cramps. Albuterol sulfate can have a significant cardiovascular effect, significant hypokalemia, and the potential life-threatening paradoxical bronchospasm. Caution is advised in patients with convulsive disorders, hyperthyroidism, diabetes mellitus, narrow-angle glaucoma, prostatic hypertrophy, or bladder-neck obstruction. Co-administration of DuoNeb® Inhalation Solution and other sympathomimetic agents may increase the risk of adverse cardiovascular effects.